Subscribe Now Subscribe Today
Research Article
 

Clinical Study of Turmeric (Curcuma longa L.) and Garlic (Allium sativum L.) Extracts as Antihyperglycemic and Antihyperlipidemic Agent in Type-2 Diabetes-Dyslipidemia Patients



E.Y. Sukandar, H. Permana, I.K. Adnyana, J.I. Sigit, R.A. Ilyas, P. Hasimun and D. Mardiyah
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
ABSTRACT

Turmeric (Curcuma longa L.) and garlic (Allium sativum Lin.) are known as traditional drugs that can cure several diseases such as dyslipidemia and diabetes. Many studies on individual usages of garlic and turmeric have been done previously. Present preclinical study showed that combination of both substances gave a better result compared to their individual usage. This research was aimed to evaluate the efficacy and safety of turmeric and garlic extracts combination as antihyperglycemic and antihyperlipidemic agents for type-2 diabetes-dyslipidemia. Three doses were evaluated: 1.2, 1.6 and 2.4 g, daily. It was found that the garlic-curcuma combination could reduce plasma glucose level and HbA1C as well as improve the lipid profile. Among those 3 dosages, the dose of 2.4 g decreased fasting glucose level, 2 h postprandial glucose level, HbA1C, total cholesterol, low density lipoprotein, triglyceride and body mass index more than the two other dosages. This dose level also increased high density lipoprotein higher than the other two dosages. There was no significant adverse event observed during the study. The treatment also showed no side effect on kidney and liver functions as well as the blood composition of all subjects.

Services
Related Articles in ASCI
Similar Articles in this Journal
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

E.Y. Sukandar, H. Permana, I.K. Adnyana, J.I. Sigit, R.A. Ilyas, P. Hasimun and D. Mardiyah, 2010. Clinical Study of Turmeric (Curcuma longa L.) and Garlic (Allium sativum L.) Extracts as Antihyperglycemic and Antihyperlipidemic Agent in Type-2 Diabetes-Dyslipidemia Patients. International Journal of Pharmacology, 6: 456-463.

DOI: 10.3923/ijp.2010.456.463

URL: https://scialert.net/abstract/?doi=ijp.2010.456.463
 
Received: April 07, 2010; Accepted: May 13, 2010; Published: September 02, 2010



INTRODUCTION

There is a growing prevalence of type-2 diabetes mellitus. Approximately 197 million people worldwide have impaired glucose tolerance. Diabetes is rapidly emerging as a global health problem which could reach pandemic levels by 2030. The number of worldwide diabetes cases is projected to increase from 171 million in 2000 to 366 million in 2030. The noticeable increase will be observed in developing countries (Hossain et al., 2007). The prevalence of type-2 diabetes mellitus varies widely among various race and ethnic groups. In Indonesia, the prevalence of type-2 diabetes mellitus was 14.7% in urban area and 7.2% in rural area. While type 2 diabetes mellitus has been usually affected individuals older than 40 years, it is being recognized that the incidence and prevalence are increasing at an alarming rate in younger person, particularly in obese children (Hossain et al., 2007).

Insulin resistance and insulin deficiency could lead to changes in plasma lipoprotein in patients with diabetes. The most common pattern of dyslipidemia in diabetes characterized by high serum triglyceride levels, low serum High Density Lipoprotein (HDL) cholesterol levels and increased concentration of serum Low Density Lipoprotein (LDL) cholesterol. Dyslipidemia in diabetes contributes to higher risk of atherosclerosis and hypertension; and subsequently to cardiovascular disease. Diabetes-related changes in plasma lipid concentrations are amenable to intervention (Eckel, 2008; Mooradian, 2009).

Herbal compounds have been proven to be beneficial in the treatment of various diseases, such as diabetes, cardiovascular disease, cancer, infection, etc. Among others, turmeric (Curcuma longa L.) and garlic (Allium sativum L.) have been used as traditional medicine for different diseases, including diabetes and hyperlipidemia. Both have shown multiple biological activities which are attributed to the reduction of risk factors of cardiovascular disease, hypoglycemic action, hypolipidemic action, antimicrobial effect and antioxidant effect (Thomson et al., 2007; Banerjee and Maulik, 2002; Ashraf et al., 2005a; Itokawa et al., 2008; Kuroda et al., 2005).

Garlic (Allium sativum) contains alliin and other sulphur compounds. When garlic cloves are crushed or disrupted, allinase enzyme, present in garlic will be activated and acts on alliin to produce allicin. Allicin has been proven to be the principal bioactive compound in garlic (Banerjee and Maulik, 2002; Ashraf et al., 2005a). Turmeric, the rhizome of Curcuma longa, is used as spice and also as medicine to treat inflammation and sprains in some Asian countries. Curcuminoid is the main component in Curcuma species and is responsible for their major biological effects. Curcumin, the major component in curcuminoid, possesses the wide range of pharmacological effects including anti-inflammatory effects, anti-oxidant activity, anti-cancer effects, reduction of blood cholesterol level, lowering blood glucose level and other biological effects (Itokawa et al., 2008; Kuroda et al., 2005; Maheshwari et al., 2006).

Our animal study showed that combination of both substances gives a better result compared to their individual usage. Ashraf et al. (2005b) also showed that garlic and turmeric combination are potent vasorelaxants and could reduce the atherogenic properties of cholesterol. In the present study, the efficacy and safety of turmeric and garlic extracts combination as hypoglycemic and hypolipidemic agents in type-2 diabetes-dyslipidemia patients were evaluated.

MATERIALS AND METHODS

A double-blind, randomized study was conducted from May 2006 until September 2007. The study protocol was approved by Ethics Committee on Research in Human, Hasan Sadikin Hospital (HSH), Bandung, Indonesia on March 17th, 2006. Written informed consent was obtained from each patient before any procedure performed.

Subjects: Patients aged from 35 to 70 years with type-2 diabetes mellitus and dyslipidemia of either sex, who had failed to comply with diet therapies, were recruited from HSH. The inclusion criteria for diabetes was indicated by fasting glucose levels >126 mg dL-1 and 2 h post-prandial (2HPP) glucose levels >200 mg dL-1, while the dyslipidemia was based on National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) indicated by total blood cholesterol >200 mg dL-1 and either LDL levels > 130 mg dL-1 or HDL levels <40 mg dL-1 or triglyceride levels >150 mg dL-1. Patients with type 1 diabetes mellitus, significant renal or hepatic dysfunction, coronary heart disease, ulcus diabetic, or have been treated with other anti-cholesterol or anti-diabetes agents (according to patients’ reports from HSH medical records), were excluded.


Fig. 1: Patient’s enrolment chart

Women, who were under hormone contraception, pregnant or lactating, were also excluded; the enrolment chart is shown in Fig. 1.

Preparation of study drugs: The capsules of study drugs contained 200 mg of turmeric ethanolic extract and 200 mg of garlic aqueous extract. The study drugs were produced by Pharmacy Installation of Indonesian Air Force.

Study design: Patients were instructed to do a diet and exercise for 2 weeks before the treatment. These activities then had to be done regularly during the study. Demographic information, daily habits, such as cigarette smoking and alcohol consumption, medical history and Body Mass Index (BMI) were recorded at the first visit. After two weeks, patients were screened again for the blood glucose level and lipid profiles based on the criteria.

Patients who failed to improve their blood glucose and lipid status after two weeks were then randomly grouped into different dosages of study drugs, i.e., group A with 1.2 g, group B: 1.6 g, or group C: 2.4 g daily for 12 weeks. Group A received 2 Allium-Curcuma (A-C) capsules + 1 placebo capsule in the morning and 1 A-C capsule + 2 placebo capsules in the evening orally. Group B received 2 A-C capsules + 1 placebo capsules in the morning and in the evening and group C received 2 times of 3 A-C capsules in the morning and in the evening.

Patients were scheduled for a regular visit, every two weeks, for three months to collect blood glucose and lipid profile data as well as the blood pressure and body weight data. A control card was given to each patient and had to be presented during visit. Patients were also asked about any adverse effects, dosage acceptance, diet obedience and any concomitant medication taken during the study in every visit.

Measurement of blood glucose, lipid profile and other haematological parameters: Blood lipids (total cholesterol, LDL, HDL and triglycerides), glucose level, were assessed at each visit. Overnight fasting blood sample was used for blood glucose and lipid profile tests. Test results from the first visit were used for screening to determine whether the subject met the inclusion criteria. The second test results were used as the baseline data. The liver function (AST, ALT), kidney function (urea, creatinine) and haematology tests were performed at the beginning, middle and end of the study to determine the safety of the drug. All the clinical tests were done in the Hasan Sadikin Hospital Laboratory.

Data analysis: The data were analyzed using a computer software package (SPSS version 14.0). Analysis of Variance (ANOVA) was used to compare the changes in parameters of interest between 3 dosage groups during the study. The significance level was set at 5%.

RESULTS AND DISCUSSION

Thirty two patients were met the inclusion criteria and were willing to follow the study. They were randomized into group A (n = 11), group B (n = 10) and group C (n = 11). The average age of group A, B and C were not statistically different. The average of fasting blood glucose level, 2HPP glucose level and HbA1c of the three groups were met the requirement of diabetes criteria. Dyslipidemia in all three groups was concluded from the average of total cholesterol, LDL, triglyceride and HDL levels. All groups showed obesity based on body mass index value. All patients were accompanied by other diseases such as hypertension, peptic ulcer, rheumatoid, or osteoporosis. Baseline characteristics of each group are shown in Table 1.

After treated with combination of garlic and turmeric for 12 weeks, group A, B and C showed a decrease of fasting glucose level by 18, 11 and 20%, respectively. However, these decreases were not statistically significant. There were insignificant decrease of 2HPP glucose for group A and B, whereas group C showed a significant decrease by 22.68% (p = 0.032). Table 2 recorded the weekly changes of fasting and 2HPP glucose levels for each group. There was a decrease of HbA1c after 12 weeks of treatment in group A, while group B showed an increase but both were statistically not significant.


Table 1: Baseline characteristic of group A, B and C
±SD values are in the brackets

Table 2: Mean of fasting and 2HPP plasma glucose levels of group A, B and C
*Statistically significant (p<0.05), SD values are in the bracket. p-value: Significant difference of blood glucose level in each observation week compared to week 0

Table 3: Lipid profiles of intention to treat (ITT) group A, B and C
±SD values are in the bracket, p-value: Significant difference of lipid levels in each observation week compared to week 0

A significant decrease of HbA1c was found in group C with average decrease of 2.77% from baseline (p = 0.025).

Table 3 showed the change of lipid profile before and after therapy for the Intent To Treat (ITT) patients, In the ITT analysis and the lipid profile showed no significant changes. Then we analysed the effect of this compound on subjects that had baseline of total cholesterol >200 mg dL-1, or LDL >150 mg dL-1, or HDL <50 mg dL-1, or triglyceride >200 mg dL-1 (Table 4). It was found that at week-8, subgroup A showed significant decrease of total cholesterol. The LDL levels decreased in the three groups but the decreases were not significant. HDL level in subgroup A and C increased significantly in week 10 and 12, respectively. Triglyceride levels showed a tendency to decrease in subgroups A and C, but they were not significant. The BMI in group A, B and C decreased by 2.6, 2.7 and 4.3%, respectively and statistically significant (Table 5).

This study supported the result of earlier study on garlic and turmeric as anti-diabetic and anti- hyperlipidemic. Both garlic and turmeric alone showed antidiabetic and antihyperlipidemic (Thomson et al., 2007; Ashraf et al., 2005a; Kuroda et al., 2005; Jang et al., 2008).

The action mechanism of turmeric as anti-diabetic could be explained that reported beneficial effects of curcumin on the liver of diabetic animals. An important enzyme that converts glucose into glycogen was higher in the diabetic mice treated with curcumin compared to the control mice. This enzyme was thought to inhibit the post-meal rise of glucose level. The anti-inflammatory and anti-oxidant properties of turmeric also have been proposed to lessen insulin resistance and prevent type-2 diabetes in mice model by dampening the inflammatory response caused by obesity. It was also found that dietary curcumin could increase the expression of adiponectin, which in turn will improve insulin sensitivity in insulin resistance animal models (Weisberg et al., 2008). Curcumin also suppressed hepatic glucose production by activating AMP kinase and inhibiting glucose-6-phosphatase and phosphoenolpyruvate carboxykinase (Fujiwara et al., 2008).

Anti-diabetic activity of garlic supported by Eidi et al. (2006) using animal study. They found that garlic extract could bring serum glucose toward normal values. Garlic extract was found to be even more effective than glibenclamide. This hypoglycemic effect was attributed mainly to allicin compound of garlic (Chang and Johnson, 1980).


Table 4: Subgroup analysis of lipid profiles in group A, B and C with total cholesterol >200 mg dL-1, or LDL >150 mg dL-1, or HDL <50 mg dL-1, or triglyceride >150 mg dL-1
*Statistical significant (p<0.05). ±SD values are in the bracket. p-value: Significant difference of lipid levels in each observation week compared to week 0

Table 5: Mean of BMI (Body Mass Index) of group A, B and C
*Statistically significant (p<0.05). ±SD values are in brackets. p value: Significant difference of BMI in each observation week compared to week 0

Though the exact mechanisms of garlic as hypoglycemic agent is still not clear several mechanisms have been suggested (Jain and Vyas, 1975; Patumraj et al., 2000; Banerjee and Maulik, 2002). Garlic may potentiate insulin effect on plasma by increasing secretion of insulin from beta cells pancreas or its release from bound insulin (Jain and Vyas, 1975). Allicin, the principal bioactive compounds in garlic extract, showed in vitro anti-oxidant and free radical scavenging effects, which may contribute to its beneficial effect in diabetes (Lau, 2001; Orekhov and Grunwald, 1997; Thomson et al., 2007).

In this study, treatment of garlic and turmeric combination for 12 weeks improved the blood glucose profile. Fasting blood glucose levels in 3 groups were decreased where the lowest was found in group C. The 2HPP plasma glucose level decreased in three groups, but only significant for group C. The level of 2HPP glucose is determined by the insulin capacity to increase the glucose intake into the tissues and also depends on tissue’s sensitivity to insulin.

Turmeric and garlic could contribute to the improvement of HbA1c level in diabetic patients. The HbA1c test is used to evaluate the glucose control and effect of the treatment within the last 8-12 weeks. The HbA1c test is a simple test because it does not require the patient to fast and also is not influenced by acute change of insulin or short term lifestyle changes, such as exercise and diet (Saudek et al., 2008). An increase of HbA1c level may contribute to the increase of diabetic complication incidence. It was also suggested that HbA1c level is a marker of pathological process related to elevated glucose levels that contribute to vascular disease risk (Selvin et al., 2005). A 1% increase in HbA1c was associated with 12% increased of heart failure (Iribarren et al., 2001). An in vitro study has demonstrated that curcumin may inhibit glycosylation of hemoglobin in high glucose concentration (Jain et al., 2006). The hypoglycemic and anti-oxidant effects of garlic and turmeric were also associated with lower blood glucose level and glycated hemoglobin (Jang et al., 2008). Turmeric and garlic combination were potential as anti-diabetic in lowering glucose and HbA1c levels and therefore they can decrease the risk factor of heart failure.

Diabetes is directly or indirectly associated with alterations in lipid profile. Evidences suggested that insulin resistance contributes in the development of dyslipidemia. Insulin resistance initiates the conditions of high triglyceride level, low HDL level and high small dense LDL level (Mooradian, 2009).

Garlic has been proposed to have direct anti-atherogenic (preventive) and anti-atherosclerotic (causing regression) effects at the artery wall (Orekhov and Grunwald, 1997). The possible mechanisms of garlic as lipid lowering agent are its inhibitory effect on hepatic activities of lipogenic and cholesterogenic enzymes such as malic enzyme, fatty acid synthase, glucose-6 phosphate dehydrogenase and 3-hydroxy-3-methyl-glutaryl-CoA (HMG CoA) reductase (Yeh and Liu, 2001). It was also suggested that garlic lowers serum lipids by delaying lipid absorption from gastrointestinal tract and diminishing LDL cholesterol synthesis in the liver (Afkhami-Ardekani et al., 2006). In an animal study, garlic supplement could significantly decrease total cholesterol, triglyceride, LDL and VLDL serum levels (Prasad et al., 2009).

Turmeric has also been shown to lower total cholesterol, triglyceride and LDL levels. The possible mechanisms have been proposed regarding anti-dyslipidemia effect of turmeric, i.e., increasing cholesterol catabolism by increasing hepatic cholesterol-7a-hydroxylase activity (Babu and Srinivasan, 1997), inhibiting cholesterol synthesis by inhibiting HMG CoA reductase (Jang et al., 2008). Curcumin was also found to increase LDL receptor (LXR), which plays a role in elimination of LDL from blood (Peschel et al., 2007) and to inhibit dietary cholesterol absorption (Arafa, 2005). In summary, we concluded that garlic and turmeric involved in regulation of lipid profile.

Garlic and turmeric combination contributed to improve lipid profile in diabetic-dyslipidemic patients. Increasing dose of turmeric and garlic combination increased HDL level. The LDL level showed no change in ITT group A, B and C. However, we observed a decrease of LDL in subgroup A, B and C among subjects with baseline LDL level >150 mg dL-1. The triglyceride level was also relatively similar in ITT group A, B and C. Among the three groups, group C showed the most consistent improvement of LDL, HDL and triglyceride levels. However, the improvement has not yet reached normal level and some were not statistically significant. The effect of turmeric and garlic combination was more effective for more severe dyslipidemia patients but this finding required further investigations using more samples. Based on this result in lipid profile of diabetic-dyslipidemic patients, turmeric and garlic is a potent combination to increase HDL level.

Present results that turmeric and garlic improved lipid profile supported by others (Orekhov and Grunwald, 1997; Lau, 2001; Hussain, 2002; Yeh and Liu, 2001; Weisberg et al., 2008). Several studies contradicted this result. Superko and Krauss (2000) showed that garlic powder supplementation for 12 weeks had no significant effect on plasma lipids and lipoprotein. It has been reported that hypocholesterolemic effect occurs only after long term dietary administration of garlic i.e., 6 months (Lau et al., 1987). Ashraf et al. (2005a) have observed that the onset of hypolipidemic effect was evident at 6th week and become more progressive and greater with time. Therefore, the modest improvement of serum lipids in our study may be due to the short term of treatment. This was supported by Duda et al. (2008) that reported the increased HDL level after short-term garlic supplementation.

In this study, the body mass index significantly decreased in all groups (p<0.05). This is in agreement with animal study that showed that dietary curcumin was associated with significantly less body weight and less body fat when compared to the control group. The curcumin-enriched diet significantly reduced the weight of Diet-Induced Obesity (DIO) mice by 2 weeks (Weisberg et al., 2008). It was also suggested that hypolipidemic effect of curcumin could be also valuable for the prevention of high-fat induced obesity (Arafa, 2005). Curcumin is known to decrease ATP biosynthesis resulted in an increase of AMP: ATP ratio and then activation of 5’-AMP kinase (AMPK). Activated AMPK would inhibit the synthesis of fatty acid and cholesterol which explains the anti-obesity effect of curcumin (Lim et al., 2009).

Adverse events were recorded during therapy every two weeks. Administration of extract combination up to 2.4 g daily did not cause any serious adverse events. The administration of the three levels of dosages for three months decreased the level of AST and ALT, ureum and creatinin, which were still within the normal limits (data not shown). These results were in agreement with previous study that administration of curcumin decreased of AST, ALT and creatinin levels (Arafa, 2005; Nwozo et al., 2009). In this study, the administration of garlic and turmeric combination up to 2.4 g daily was found to be safe and well tolerated. Our teratogenicity study in mice showed that the combination of turmeric and garlic extract of 1000 mg kg-1 b.wt. each, which is equivalent to 11.20 g of each extract in human, was safe to fetus of mice (Sukandar et al., 2008).

Combination of turmeric and garlic extracts showed a better antidyslipidemia and antidiabetes effect compared to its single usage. We suspected that the side effects from garlic usage could be attenuated by turmeric. For example, gastrointestinal disorder caused by garlic usage was compensated by turmeric which has been proved to improve gastrointestinal disorder in irritable bowel syndrome (Bundy et al., 2004; Coon and Ernst, 2002). According to Tiwari and Rao (2002), there is advantage of polyherbal over monoherbal therapy. Polyherbal therapy may have synergistic, potentiative, agonist/antagonist pharmacological effect within themselves that produce therapeutic efficacy with minimum side effects (Eyong et al., 2008). Turmeric also stabilizes the allicin in garlic extract towards chemical degrade and furthermore reduces the bad odor from garlic caused by its sulfuric compound.

CONCLUSIONS

The results of this study showed that administration of garlic and turmeric combination decreased the plasma glucose levels and improved the lipid profiles of type-2 diabetic-dyslipidemic patients. It also significantly decreased the BMI. The safety data also showed that 3 months administration of the extract combination for all dosage levels were safe and well tolerated.

ACKNOWLEDGMENTS

The authors would like to thank Innogene Kalbiotech Pte. Ltd. for the research grant. We also address our gratitude and appreciation to Wenny Yang, MD, Vinci Lorensia, MD, Vita Kurniati, MD, Ph.D. for preparing the manuscript; Rucita Sapphira Lazuardi, BSc. and Cecilia Anggraini, M.Sc. for statistical analysis.

REFERENCES
1:  Afkhami-Ardekani, M., A.R. Kamali-Ardekani and A. Shojaoddiny-Ardekani, 2006. Effects of garlic on serum lipids and blood glucose of type 2 diabetic patients. Int. J. Diab. Dev. Countries, 26: 86-88.
Direct Link  |  

2:  Arafa, H.M., 2005. Curcumin attenuates diet induced hypercholesterolemia in rats. Med. Sci. Monit., 11: 228-234.
Direct Link  |  

3:  Ashraf, R., K. Aamir, A.R. Shaikh and T. Ahmed, 2005. Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus. J. Ayub. Med. Coll. Abbottabad, 17: 60-64.
PubMed  |  Direct Link  |  

4:  Ashraf, Z.A., M.E. Hussain and M. Fahim, 2005. Antiatherosclerotic effects of dietary supplementations of garlic and turmeric: Restoration of endothelial function in rats. Life Sci., 77: 837-857.
CrossRef  |  Direct Link  |  

5:  Babu, P.S. and K. Srinivasan, 1997. Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Mol. Cell. Biochem., 166: 169-175.
CrossRef  |  PubMed  |  Direct Link  |  

6:  Banerjee, S.K. and S.K. Maulik, 2002. Effect of garlic on cardiovascular disorders: A review. Nutr. J., Vol. 1. 10.1186/1475-2891-1-4

7:  Bundy, R., A.F. Walker, R.W. Middleton and J. Booth, 2004. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: A pilot study. J. Alter. Complement. Med., 10: 1015-1018.
PubMed  |  

8:  Chang, M.L. and M.A. Johnson, 1980. Effect of garlic on carbohydrate metabolism and lipid synthesis in rats. J. Nutr., 110: 931-936.
PubMed  |  

9:  Coon, J.T. and E. Ernst, 2002. Systematic review: Herbal medicinal products for non-ulcer dyspepsia. Aliment. Pharmacol. Ther., 16: 1689-1699.
PubMed  |  Direct Link  |  

10:  Duda, G., J. Suliburska and D. Pupek-Musialik, 2008. Effects of short-term garlic supplementation on lipid metabolism and antioxidant status in hypertensive adults. Pharmacol. Rep., 60: 163-170.
PubMed  |  

11:  Ebong, P.E., I.J. Atangwho, E.U. Eyong and G.E. Egbung, 2008. The antidiabetic efficacy of combined extracts from two continental plants: Azadirachta indica (A. Juss) (Neem) and Vernonia amygdalina (Del.) (African Bitter leaf). Am. J. Biochem. Biotehcnol., 4: 239-244.
CrossRef  |  Direct Link  |  

12:  Eckel, R.H., 2008. Diabetic dyslipidemia and cardiovascular risk. Curr. Diabetes Reports, 8: 421-423.
CrossRef  |  

13:  Eidi, A., M. Eidi and E. Esmaeili, 2006. Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats. Phytomedicine, 13: 624-629.
CrossRef  |  PubMed  |  Direct Link  |  

14:  Fujiwara, H., M. Hosokawa, X. Zhou, S. Fujimoto and K. Fukuda et al., 2008. Curcumin inhibits glucose production in isolated mice hepatocytes. Diabetes Res. Clin. Pract., 80: 185-191.
PubMed  |  

15:  Hossain, P., B. Kawar and M. El Nahas, 2007. Obesity and diabetes in the developing world-A growing challenge. New Eng. J. Med., 356: 213-215.
CrossRef  |  Direct Link  |  

16:  Hussain, H.E.M.A., 2002. Hypoglycemic, hypolipidemic and antioxidant properties of combination of Curcumin from Curcuma longa, Linn and partially purified product from Abroma augusta, Linn. in streptozotocin induced diabetes. Indian J. Clin. Biochem., 17: 33-43.
CrossRef  |  Direct Link  |  

17:  Iribarren, C., A.J. Karter, A.S. Go, A. Ferrara, J.Y. Liu, S. Sidney and J.V. Selby, 2001. Glycemic control and heart failure among adult patients with diabetes. Circulation, 103: 2668-2673.
PubMed  |  

18:  Itokawa, H., Q. Shi, T. Akiyama, S.L. Morris-Natschke and K.H. Lee, 2008. Recent advances in the investigation of curcuminoids. Chin. Med., 3: 11-11.
CrossRef  |  

19:  Jain, R.C. and C.R. Vyas, 1975. Garlic in alloxan-induced diabetic rabbits. Am. J. Clin. Nutr., 28: 684-685.
PubMed  |  

20:  Jain, S.K., J. Rains and K. Jones, 2006. Effect of curcumin on protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels. Free Radical Biol. Med., 41: 92-96.
CrossRef  |  PubMed  |  Direct Link  |  

21:  Jang, E.M., M.S. Choi, U.J. Jung, M.J. Kim and H.J. Kim et al., 2008. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamster. Metabolism, 57: 1576-1583.
PubMed  |  

22:  Lau, B.H.S., F. Lam and R. Wang-Cheng, 1987. Effect of an odor-modified garlic preparation on blood lipids. Nutr. Res., 7: 139-149.
CrossRef  |  Direct Link  |  

23:  Lau, B.H., 2001. Suppression of LDL oxidation by garlic. J. Nutr., 131: 985S-988S.
PubMed  |  Direct Link  |  

24:  Lim, H.W., H.Y. Lim and K.P. Wong, 2009. Uncoupling of oxidative phosphorylation by curcumin: Implication of its cellular mechanism of action. Biochem. Biophys. Res. Com., 389: 187-192.
PubMed  |  

25:  Maheshwari, R.K., A.K. Singh, J. Gaddipati and R.C. Srimal, 2006. Multiple biological activities of curcumin: A short review. Life Sci., 78: 2081-2087.
CrossRef  |  Direct Link  |  

26:  Mooradian, A.D., 2009. Dyslipidemia in type 2 diabetes mellitus. Nat. Rev. Endocrinol., 5: 150-159.
CrossRef  |  PubMed  |  Direct Link  |  

27:  Nwozo, S., O. Adaramoye and E. Ajaiyeoba, 2009. Oral administration of extract from Curcuma longa lowers blood glucose and attenuates alloxan-induced hyperlipidemia in diabetic rabbits. Pak. J. Nutr., 8: 625-628.
CrossRef  |  Direct Link  |  

28:  Orekhov, A.N. and J. Grunwald, 1997. Effects of garlic on atherosclerosis. Nutrition, 13: 656-663.
PubMed  |  

29:  Patumraj, S., S. Tewit, S. Amatyakul, A. Jariyapongskul, S. Maneesri, V. Kasantikul and D. Shepro, 2000. Comparative effects of garlic and aspirin on diabetic cardiovascular complications. Drug Deliv., 7: 91-96.
Direct Link  |  

30:  Peschel, D., R. Koerting and N. Nass, 2007. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J. Nutr. Biochem., 18: 113-119.
CrossRef  |  

31:  Prasad, R., M.K. Rose, M. Virmani, S.L. Garg and J.P. Puri, 2009. Lipid profile of chicken (Gallus domesticus) in response to dietary supplementation of garlic (Allium sativum). Int. J. Poult. Sci., 8: 270-276.
CrossRef  |  Direct Link  |  

32:  Saudek, C.D., W.H. Herman, D.B. Sacks, R.M. Bergenstal, D. Edelman and M.B. Davidson, 2008. A new look at screening and diagnosing diabetes mellitus. J. Clin. Endocrinol. Metab., 93: 2447-2453.
CrossRef  |  

33:  Selvin, E., J. Coresh, S.H. Golden, F.L. Brancati, A.R. Folsom and M.W. Steffes, 2005. Glycemic control and coronary heart disease risk in persons with and without diabetes. Arch. Int. Med., 165: 1910-1916.
PubMed  |  

34:  Sukandar, E.Y., I. Fidrianny and A.N. Garmana, 2008. Effect of garlic and turmeric extracts on Swiss-Webster mice fetus. J. Kedokt. Maranatha., 8: 36-44.

35:  Superko, H.R. and R.M. Krauss, 2000. Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein(a). J. Am. Coll. Cardiol., 35: 321-326.
CrossRef  |  PubMed  |  Direct Link  |  

36:  Tiwari, A.K. and J.M. Rao, 2002. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. Curr. Sci., 83: 30-38.
Direct Link  |  

37:  Thomson, M., Z.M. Al-Amin, K.K. Al-Qattan, L.H. Shaban and M. Ali, 2007. Anti-diabetic and hypolipidaemic properties of garlic (Allium sativum) in streptozotocin-induced diabetic rats. Int. J. Diabetes Metabol., 15: 108-115.
Direct Link  |  

38:  Weisberg, S.P., R. Leibel and D.V. Tortoriello, 2008. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology, 149: 3549-3558.
CrossRef  |  PubMed  |  Direct Link  |  

39:  Yeh, Y.Y. and L. Liu, 2001. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: Human and animal studies. J. Nutr., 131: 989S-993S.
Direct Link  |  

40:  Kuroda, M., Y. Mimaki, T. Nishiyama, T. Mae and H. Kishida et al., 2005. Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-Ay mice. Biol. Pharm. Bull., 28: 937-939.
CrossRef  |  PubMed  |  Direct Link  |  

©  2021 Science Alert. All Rights Reserved